Cencora, Inc. (NYSE:COR) Shares Sold by Vontobel Holding Ltd.

Vontobel Holding Ltd. lessened its stake in Cencora, Inc. (NYSE:COR - Free Report) by 20.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,995 shares of the company's stock after selling 1,250 shares during the quarter. Vontobel Holding Ltd.'s holdings in Cencora were worth $1,389,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in COR. Hoey Investments Inc. purchased a new position in shares of Cencora in the 1st quarter worth $28,000. Banque Transatlantique SA acquired a new stake in Cencora during the fourth quarter worth about $29,000. SBI Securities Co. Ltd. purchased a new position in shares of Cencora in the 4th quarter worth about $30,000. Vermillion Wealth Management Inc. acquired a new position in shares of Cencora in the 4th quarter valued at about $38,000. Finally, OFI Invest Asset Management purchased a new stake in shares of Cencora during the 4th quarter worth about $41,000. Institutional investors and hedge funds own 97.52% of the company's stock.

Cencora Stock Up 1.7%

Shares of COR traded up $5.06 during trading on Friday, reaching $296.23. The company's stock had a trading volume of 614,990 shares, compared to its average volume of 1,504,083. The company has a market cap of $57.42 billion, a price-to-earnings ratio of 34.37, a P/E/G ratio of 1.47 and a beta of 0.57. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 6.01. The company has a fifty day moving average of $291.12 and a two-hundred day moving average of $267.23. Cencora, Inc. has a twelve month low of $218.65 and a twelve month high of $309.35.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. The firm had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The firm's revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.80 EPS. On average, sell-side analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a yield of 0.74%. Cencora's dividend payout ratio (DPR) is 25.52%.

Insider Activity

In related news, Chairman Steven H. Collis sold 14,579 shares of the firm's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the transaction, the chairman directly owned 311,913 shares in the company, valued at $91,271,982.06. This trade represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Robert P. Mauch sold 4,969 shares of Cencora stock in a transaction on Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the completion of the transaction, the chief executive officer directly owned 47,582 shares of the company's stock, valued at approximately $13,766,900.06. This represents a 9.46% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 34,127 shares of company stock valued at $9,812,296. 10.80% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

COR has been the topic of a number of recent research reports. Citigroup lifted their price target on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Morgan Stanley set a $288.00 target price on shares of Cencora in a report on Tuesday, April 15th. Bank of America increased their price target on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a report on Friday, April 11th. Wells Fargo & Company raised Cencora from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $274.00 to $337.00 in a research report on Tuesday, June 3rd. Finally, UBS Group raised their target price on Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $306.33.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.